Company Overview - Minovia Therapeutics Ltd. is a clinical-stage biotechnology company focused on developing therapies for mitochondrial diseases and age-related decline [1][5] - The company is working on its main drug product, MNV-201, which is currently being tested for Pearson Syndrome and Myelodysplastic Syndrome [5] Recent Developments - Minovia has been awarded a $350,000 grant from Countdown for a Cure to develop novel mitochondrial blood-based biomarkers [1][2] - The grant will fund clinical operations for blood sample collection from approximately 30 patients with primary mitochondrial diseases and 140 samples from healthy controls [2] Research and Development - The company aims to develop blood-based functional mitochondrial biomarkers to identify patients who may benefit from its proprietary mitochondrial augmentation technology (MAT) [2] - A clinical trial has been initiated at Sheba Medical Center to collect blood samples for analysis and to determine a "MitoScore" for each sample [2] Market Need - Mitochondrial dysfunction is associated with rare genetic mitochondrial diseases and chronic age-related diseases, with a significant unmet need for effective treatments [3] - Currently, there are no approved therapies for mitochondrial dysfunction, nor functional tests to diagnose and quantify it [3] Business Combination - Minovia has entered into a definitive business combination agreement with Launch One Acquisition Corp., a publicly traded special purpose acquisition company [4] - The transaction is expected to close in late 2025, after which the combined company will operate as Minovia Therapeutics and trade on Nasdaq under a new ticker symbol [4]

Company Overview - Thiogenesis Therapeutics, Corp. is a clinical-stage biopharmaceutical company focused on developing sulfur-based therapeutics for rare pediatric and inherited mitochondrial disorders [2][10] - The company is publicly traded on the TSX Venture Exchange and OTCQX [10] Clinical Programs - The company is advancing two lead Phase 2 clinical programs for its novel thiol drug, TTI-0102 [3] - A European multicenter trial for Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS), initiated on May 14, 2025 [3] - A U.S.-based trial for the Leigh Syndrome Spectrum (LSS), following FDA clearance of the Investigational New Drug (IND) application on June 11, 2025 [3] Drug Candidate - TTI-0102 is a next-generation thiol-based prodrug designed to enhance intracellular levels of glutathione and taurine, which are critical for mitigating oxidative stress in mitochondrial disorders [3][8] - The drug is engineered to address challenges faced by first-generation thiol-based drugs, including short half-life and adverse side effects [8] Mitochondrial Disorders - MELAS is characterized by symptoms such as seizures, muscle weakness, and can lead to loss of motor skills and intellectual disability, affecting approximately 4.1 in 100,000 of the population [7] - LSS is diagnosed in about 1 in 40,000 births and presents symptoms like impaired feeding, loss of motor skills, and seizures, with no current cure available [6] Conference Participation - The company’s CEO, Dr. Patrice Rioux, will participate in a clinical panel discussion at the United Mitochondrial Disease Foundation's 2025 Mitochondrial Medicine Conference, which gathers over 700 scientists and industry stakeholders [2][3]